133 related articles for article (PubMed ID: 17234022)
1. Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
Chauhan D; Miners AH; Fischer AJ
Int J Technol Assess Health Care; 2007; 23(1):96-100. PubMed ID: 17234022
[TBL] [Abstract][Full Text] [Related]
2. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.
Miners AH; Garau M; Fidan D; Fischer AJ
BMJ; 2005 Jan; 330(7482):65. PubMed ID: 15601681
[TBL] [Abstract][Full Text] [Related]
3. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
4. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
Tosh JC; Longworth LJ; George E
Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
[TBL] [Abstract][Full Text] [Related]
5. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
Wang S; Gum D; Merlin T
Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
[TBL] [Abstract][Full Text] [Related]
6. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
7. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
8. The role of NICE technology appraisal in NHS rationing.
Walker S; Palmer S; Sculpher M
Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
[TBL] [Abstract][Full Text] [Related]
9. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
10. The cost of a QALY.
Kirkdale R; Krell J; Brown CO; Tuthill M; Waxman J
QJM; 2010 Sep; 103(9):715-20. PubMed ID: 20519275
[TBL] [Abstract][Full Text] [Related]
11. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
Gallacher D; Auguste P; Connock M
Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
[TBL] [Abstract][Full Text] [Related]
12. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
13. Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health.
Hamers FF; Ghabri S; Le Gales C
Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):489-494. PubMed ID: 28133977
[TBL] [Abstract][Full Text] [Related]
14. Using health outcomes data to inform decision-making: government agency perspective.
Taylor R
Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.
Tai TA; Latimer NR; Benedict Á; Kiss Z; Nikolaou A
Value Health; 2021 Apr; 24(4):505-512. PubMed ID: 33840428
[TBL] [Abstract][Full Text] [Related]
17. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
Kaltenthaler E; Papaioannou D; Boland A; Dickson R
Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
[TBL] [Abstract][Full Text] [Related]
18. Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold.
Griffiths EA; Hendrich JK; Stoddart SD; Walsh SC
Clinicoecon Outcomes Res; 2015; 7():463-76. PubMed ID: 26366099
[TBL] [Abstract][Full Text] [Related]
19. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
Towse A; Pritchard C
Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
[TBL] [Abstract][Full Text] [Related]
20. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.
Morton A; Adler AI; Bell D; Briggs A; Brouwer W; Claxton K; Craig N; Fischer A; McGregor P; van Baal P
Health Econ; 2016 Aug; 25(8):933-8. PubMed ID: 27374115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
